<DOC>
	<DOCNO>NCT02736721</DOCNO>
	<brief_summary>This study evaluate efficacy , safety tolerability long-term use peginterferon alfa-2a participant CML previously participate peginterferon alfa-2a study ML16544 ( NCT number available ) , NO16006 ( NCT number available ) ML17228 ( NCT number available ) treat physician decide continue treatment peginterferon alfa-2a within frame another clinical study .</brief_summary>
	<brief_title>Expanded Access Study With Peginterferon Alfa-2a ( Pegasys ) Participants With Chronic Myelogenous Leukemia ( CML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Participants CML Previous participation study : ML16544 , NO16006 ML17228 ; treat physician recommends continuation study drug accord define minimal criterion Major protocol violator participate study prior participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>